Skip to content

Azilva Tablets special drug use surveillance: Long-term use

Azilva Tablets special drug use surveillance: Long-term use

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222391
Enrollment
3000
Registered
2014-02-10
Start date
2014-02-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Sponsors

TAKEDA PHARMACEUTICAL COMPANY LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with a history of hypersensitivity to any of the ingredients of in azilsartan. 2. Patients who are pregnant or having possibilities of being pregnant

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Frequency of adverse drug reactions Primary timeframe12 months The frequencies of all adverse drug reactions observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended all of signs, symptoms or diseases temporally associated with administration of azilsartan,whether or not it was considered related to the treatment. Among these, events which are considered to have a casual relationship with azilsartan are defined as adverse drug reactions.

Secondary

MeasureTime frame
Change in blood pressure Secondary timeframeFrom baseline to 12 months Tabulation of actual measured value and changes from baseline at each test time point in blood pressure (test value at each test time point after baseline - test value at baseline)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026